 | This article is rated Start-class on Wikipedia's
content assessment scale. It is of interest to the following WikiProjects: | |||||||||||||
| ||||||||||||||
 | Ideal sources for Wikipedia's health content are defined in the guideline
Wikipedia:Identifying reliable sources (medicine) and are typically
review articles. Here are links to possibly useful sources of information about Chronic eosinophilic leukemia.
|
Imatinib is used in PDGFRA-FIL1P1 fusion, but it turns out that a very low weekly dose is sufficient: http://www.blackwell-synergy.com/doi/abs/10.1111/j.1365-2141.2008.07033.x JFW | T@lk 11:06, 25 March 2008 (UTC)
|
| This article is rated Start-class on Wikipedia's
content assessment scale. It is of interest to the following WikiProjects: | |||||||||||||
| ||||||||||||||
|
| Ideal sources for Wikipedia's health content are defined in the guideline
Wikipedia:Identifying reliable sources (medicine) and are typically
review articles. Here are links to possibly useful sources of information about Chronic eosinophilic leukemia.
|
Imatinib is used in PDGFRA-FIL1P1 fusion, but it turns out that a very low weekly dose is sufficient: http://www.blackwell-synergy.com/doi/abs/10.1111/j.1365-2141.2008.07033.x JFW | T@lk 11:06, 25 March 2008 (UTC)